Junor B J, d'Apice A J, Kincaid-Smith P
Transplantation. 1980 Aug;30(2):111-3. doi: 10.1097/00007890-198008000-00006.
The liquid phase C1q-binding assay was used as a measure of circulating immune complexes in 147 renal transplant recipients. Thirty-six patients were studied serially from the time of transplantation. Abnormal levels of C1q-binding activity (C1qBA) were most frequently detected in the first 6 months post-transplant. Although there was a statistically significant association of elevated C1qBA with rejection, the incidence of "false positives" and "false negatives" was high and particularly evident in serial studies. There was no evidence of association between C1qBA and the recipients' original renal diseases. Post-transplant monitoring of renal transplant recipients for circulating immune complexes by the C1q-binding assay is an unreliable guide to rejection.
液相C1q结合试验被用于检测147例肾移植受者循环免疫复合物水平。36例患者自移植后开始接受连续监测。移植后前6个月最常检测到C1q结合活性(C1qBA)异常。虽然C1qBA升高与排斥反应存在统计学显著相关性,但“假阳性”和“假阴性”发生率较高,在连续监测中尤为明显。没有证据表明C1qBA与受者原有的肾脏疾病有关。通过C1q结合试验对肾移植受者进行循环免疫复合物的移植后监测,对于排斥反应是不可靠的指标。